Cargando…

Polymorphisms in the promoter region of the CRBN gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients

Cereblon is a primary molecular target for immunomodulatory drugs. The aim of this study was to evaluate the influence of selected clinical and molecular factors including single nucleotide polymorphisms (SNPs) in CRBN gene on the efficacy of first line CTD (cyclophosphamide, thalidomide, dexamethas...

Descripción completa

Detalles Bibliográficos
Autores principales: Szudy-Szczyrek, Aneta, Mlak, Radosław, Szczyrek, Michał, Chocholska, Sylwia, Sompor, Jacek, Nogalski, Adam, Małecka-Massalska, Teresa, Hus, Marek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5963627/
https://www.ncbi.nlm.nih.gov/pubmed/29844872
http://dx.doi.org/10.18632/oncotarget.25307
_version_ 1783325056664862720
author Szudy-Szczyrek, Aneta
Mlak, Radosław
Szczyrek, Michał
Chocholska, Sylwia
Sompor, Jacek
Nogalski, Adam
Małecka-Massalska, Teresa
Hus, Marek
author_facet Szudy-Szczyrek, Aneta
Mlak, Radosław
Szczyrek, Michał
Chocholska, Sylwia
Sompor, Jacek
Nogalski, Adam
Małecka-Massalska, Teresa
Hus, Marek
author_sort Szudy-Szczyrek, Aneta
collection PubMed
description Cereblon is a primary molecular target for immunomodulatory drugs. The aim of this study was to evaluate the influence of selected clinical and molecular factors including single nucleotide polymorphisms (SNPs) in CRBN gene on the efficacy of first line CTD (cyclophosphamide, thalidomide, dexamethasone) chemotherapy in patients with multiple myeloma. Study group consisted of 68 patients. Analysis of CRBN gene SNPs (rs6768972, rs1672753) was performed using Real-Time PCR genotyping technique. Median progression free survival (PFS) was 15 months and overall survival (OS) 79 months. Factors associated with significantly shorter OS included ISS 3, kidney disease, weight loss, anemia, thrombocytopenia, hypoalbuminemia, elevated β2-microglobuline and CRP. The presence of t(4;14) was associated with significantly shorter PFS and OS. Both examined SNPs proved to be statistically significant, independent predictive factors of efficacy of the CTD chemotherapy. The presence of AA genotype (rs6768972) correlated with longer median PFS (18 vs 9 months; HR=0.49,95% CI: 0.26-0.91, p=0.0062). Conversely, in the carriers of CC genotype (rs1672753) significantly shorter median PFS was observed (4 vs 16 months; HR=3.93, 95% CI: 0.26-59.64, p=0.0321). In conclusion, SNPs of the CRBN gene may be useful in qualifying patients for treatment with regimens containing thalidomide.
format Online
Article
Text
id pubmed-5963627
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-59636272018-05-29 Polymorphisms in the promoter region of the CRBN gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients Szudy-Szczyrek, Aneta Mlak, Radosław Szczyrek, Michał Chocholska, Sylwia Sompor, Jacek Nogalski, Adam Małecka-Massalska, Teresa Hus, Marek Oncotarget Research Paper Cereblon is a primary molecular target for immunomodulatory drugs. The aim of this study was to evaluate the influence of selected clinical and molecular factors including single nucleotide polymorphisms (SNPs) in CRBN gene on the efficacy of first line CTD (cyclophosphamide, thalidomide, dexamethasone) chemotherapy in patients with multiple myeloma. Study group consisted of 68 patients. Analysis of CRBN gene SNPs (rs6768972, rs1672753) was performed using Real-Time PCR genotyping technique. Median progression free survival (PFS) was 15 months and overall survival (OS) 79 months. Factors associated with significantly shorter OS included ISS 3, kidney disease, weight loss, anemia, thrombocytopenia, hypoalbuminemia, elevated β2-microglobuline and CRP. The presence of t(4;14) was associated with significantly shorter PFS and OS. Both examined SNPs proved to be statistically significant, independent predictive factors of efficacy of the CTD chemotherapy. The presence of AA genotype (rs6768972) correlated with longer median PFS (18 vs 9 months; HR=0.49,95% CI: 0.26-0.91, p=0.0062). Conversely, in the carriers of CC genotype (rs1672753) significantly shorter median PFS was observed (4 vs 16 months; HR=3.93, 95% CI: 0.26-59.64, p=0.0321). In conclusion, SNPs of the CRBN gene may be useful in qualifying patients for treatment with regimens containing thalidomide. Impact Journals LLC 2018-05-08 /pmc/articles/PMC5963627/ /pubmed/29844872 http://dx.doi.org/10.18632/oncotarget.25307 Text en Copyright: © 2018 Szudy-Szczyrek et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Szudy-Szczyrek, Aneta
Mlak, Radosław
Szczyrek, Michał
Chocholska, Sylwia
Sompor, Jacek
Nogalski, Adam
Małecka-Massalska, Teresa
Hus, Marek
Polymorphisms in the promoter region of the CRBN gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients
title Polymorphisms in the promoter region of the CRBN gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients
title_full Polymorphisms in the promoter region of the CRBN gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients
title_fullStr Polymorphisms in the promoter region of the CRBN gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients
title_full_unstemmed Polymorphisms in the promoter region of the CRBN gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients
title_short Polymorphisms in the promoter region of the CRBN gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients
title_sort polymorphisms in the promoter region of the crbn gene as a predictive factor for the first-line ctd therapy in multiple myeloma patients
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5963627/
https://www.ncbi.nlm.nih.gov/pubmed/29844872
http://dx.doi.org/10.18632/oncotarget.25307
work_keys_str_mv AT szudyszczyrekaneta polymorphismsinthepromoterregionofthecrbngeneasapredictivefactorforthefirstlinectdtherapyinmultiplemyelomapatients
AT mlakradosław polymorphismsinthepromoterregionofthecrbngeneasapredictivefactorforthefirstlinectdtherapyinmultiplemyelomapatients
AT szczyrekmichał polymorphismsinthepromoterregionofthecrbngeneasapredictivefactorforthefirstlinectdtherapyinmultiplemyelomapatients
AT chocholskasylwia polymorphismsinthepromoterregionofthecrbngeneasapredictivefactorforthefirstlinectdtherapyinmultiplemyelomapatients
AT somporjacek polymorphismsinthepromoterregionofthecrbngeneasapredictivefactorforthefirstlinectdtherapyinmultiplemyelomapatients
AT nogalskiadam polymorphismsinthepromoterregionofthecrbngeneasapredictivefactorforthefirstlinectdtherapyinmultiplemyelomapatients
AT małeckamassalskateresa polymorphismsinthepromoterregionofthecrbngeneasapredictivefactorforthefirstlinectdtherapyinmultiplemyelomapatients
AT husmarek polymorphismsinthepromoterregionofthecrbngeneasapredictivefactorforthefirstlinectdtherapyinmultiplemyelomapatients